文献速递神经肿瘤

使用定量MRI特征对II/III级胶质瘤患者进行分子分型

Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
PubMed 文献 · J Neurooncol · 2018-06-02

本研究纳入61例放疗前有分子数据和MRI的II/III级胶质瘤患者,提取FLAIR定量异质性和边界清晰度特征,发现IDH野生型、1p/19q共缺失和MGMT甲基化肿瘤各有不同影像特征,联合特征可优化IDH状态分类。

要点

  • IDH野生型较突变型FLAIR信号异质性更高(p=0.001)、边界对比度更低(p=0.008)。
  • IDH突变型中1p/19q共缺失者较完整者异质性更高(p=0.002)、边界对比度更低(p=0.005)。
  • MGMT甲基化组较未甲基化组边界对比度更低(p=0.03)。

核心结论

  • II/III级胶质瘤FLAIR异质性和边界模式的定量影像特征可能为初始诊断影像时判断分子状态提供独特信息,进而可能指导后续手术和药物治疗。

研究设计与样本

  • 纳入61例II/III级胶质瘤患者,均有分子数据和放疗前MRI。
  • 提取定量MRI特征测量组织异质性(均匀性和像素相关性)和FLAIR边界清晰度(边缘对比度,EC)。
  • 采用t检验比较不同基因型患者特征差异,并用LASSO正则化逻辑回归确定预测分子亚型的最佳MRI和临床特征组合。

主要发现

  • IDH野生型肿瘤较IDH突变型肿瘤FLAIR区域信号异质性更高(p=0.001)、EC更低(p=0.008)。
  • IDH突变型肿瘤中,1p/19q共缺失肿瘤较1p/19q完整肿瘤信号异质性更高(p=0.002)、EC更低(p=0.005)。
  • MGMT甲基化肿瘤较未甲基化组EC更低(p=0.03)。
  • FLAIR边界清晰度、异质性和像素相关性的组合最佳分类IDH状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular markers of WHO grade II/III glioma are known to have important prognostic and predictive implications and may be associated with unique imaging phenotypes. The purpose of this study is to determine whether three clinically relevant molecular markers identified in gliomas-IDH, 1p/19q, and MGMT status-show distinct quantitative MRI characteristics on FLAIR imaging. METHODS: Sixty-one patients with grade II/III gliomas who had molecular data and MRI available prior to radiation were included. Quantitative MRI features were extracted that measured tissue heterogeneity (homogeneity and pixel correlation) and FLAIR border distinctiveness (edge contrast; EC). T-tests were conducted to determine whether patients with different genotypes differ across the features. Logistic regression with LASSO regularization was used to determine the optimal combination of MRI and clinical features for predicting molecular subtypes. RESULTS: Patients with IDH wildtype tumors showed greater signal heterogeneity (p = 0.001) and lower EC (p = 0.008) within the FLAIR region compared to IDH mutant tumors. Among patients with IDH mutant tumors, 1p/19q co-deleted tumors had greater signal heterogeneity (p = 0.002) and lower EC (p = 0.005) compared to 1p/19q intact tumors. MGMT methylated tumors showed lower EC (p = 0.03) compared to the unmethylated group. The combination of FLAIR border distinctness, heterogeneity, and pixel correlation optimally classified tumors by IDH status. CONCLUSION: Quantitative imaging characteristics of FLAIR heterogeneity and border pattern in grade II/III gliomas may provide unique information for determining molecular status at time of initial diagnostic imaging, which may then guide subsequent surgical and medical management.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bahrami N, Hartman SJ, Chang YH, et al. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics. J Neurooncol. 2018. PMID: 29860714. doi:10.1007/s11060-018-2908-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。